Researchers examined the selective vulnerability of the cholinergic system in Alzheimer disease (AD) by exploring the severity of accumulation and neuronal loss in the nucleus basalis of Meynert among AD subtypes.
Higher serum levels of elaidic acid, an objective biomarker for industrial trans fat, are associated with an increased risk for developing all-cause dementia and Alzheimer disease.
Low and high hemoglobin levels were associated with increased risk for dementia, white matter hyperintensity volume, and structural connectivity.
Alzheimer disease patients who initiate treatment with antipsychotic medications spend more days hospitalized than those who do not initiate antipsychotics.
In older adults, BMI-adjusted waist circumference was positively associated with the incidence of dementia.
The FDA has granted Fast Track designation to neflamapimod (EIP Pharma) for the treatment of dementia with Lewy bodies (DLB).
Early-stage Alzheimer disease seems to put households at risk for large adverse changes in liquid assets and may reduce net wealth.
Company claimed their CBD products can be used to treat a variety of conditions and diseases including teething pain and earaches in infants, skin problems, autism, ADHD, Parkinson disease, and Alzheimer disease, among others.
Compared with placebo, high dose aducanumab was associated with significant reduction of clinical decline in patients with early Alzheimer disease, as measured by the change from baseline in Clinical Dementia Rating-Sum of Boxes score at 78 weeks.
For adults with dementia, nonpharmacologic interventions seem to be more efficacious than pharmacologic interventions for reducing aggression and agitation.
